Actively Recruiting
Phase 3 Randomized Study of Zanzalintinib Alone or with Pembrolizumab and Berahyaluronidase Alfa Versus Placebo in Stage IIIII Colorectal Cancer With Molecular Residual Disease After Definitive Therapy
Led by Exelixis · Updated on 2026-09-21
600
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of zanzalintinib alone and in combination with pembrolizumab plus berahyaluronidase alfa compared with placebo in participants with colorectal cancer who have molecular residual disease after definitive therapy. This phase 3 randomized study focuses on patients with stage II or III colorectal adenocarcinoma confirmed by molecular and imaging tests. The goal is to determine if these treatments improve disease-free survival and other outcomes over up to 24 months. Participants are assigned to one of three groups one group receives zanzalintinib plus pembrolizumab and berahyaluronidase alfa, another receives zanzalintinib alone, and the third receives placebo matching zanzalintinib. Zanzalintinib is given orally once daily, while the combination therapy includes subcutaneous injections of pembrolizumab plus berahyaluronidase alfa every three weeks. Treatments continue for up to two years. During the study, participants undergo regular assessments including imaging scans to confirm no visible disease, molecular testing for circulating tumor DNA clearance, and evaluations of overall survival and adverse events. Disease-free survival is the main outcome measured by investigators over 24 months. Safety and effectiveness data are collected throughout treatment and follow-up periods to monitor participant health and response to therapies.
CONDITIONS
Brief Title
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Research Team
E
Exelixis Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here